NCT04743622

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: CHA University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study

Detailed description

Not provided

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Monoprost	preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes
DRUG	Xalatan	preserved latanoprost 1 drop once a day for 12 weeks to target eyes

Timeline

• Start date: 2019-04-30
• Primary completion: 2020-06-23
• Completion: 2020-09-13
• First posted: 2021-02-08
• Last updated: 2021-02-08

Locations

1 site across 1 country: South Korea